scispace - formally typeset
A

Allison F. Vitonis

Researcher at Brigham and Women's Hospital

Publications -  127
Citations -  4569

Allison F. Vitonis is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Ovarian cancer & Endometriosis. The author has an hindex of 36, co-authored 127 publications receiving 3770 citations.

Papers
More filters
Journal ArticleDOI

Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment: Commentary

TL;DR: Pregnancy is not "protective" with respect to risk of relapse of major depression, and women with histories of depression who are euthymic in the context of ongoing antidepressant therapy should be aware of the association of depressive relapse during pregnancy with antidepressant discontinuation.
Journal ArticleDOI

World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research

TL;DR: This is the first multicenter, international collaboration between academic centers and industry addressing standardization of phenotypic data collection for a specific disease, and SSF and MSF are essential tools to increase the understanding of the pathogenesis of endometriosis by allowing large-scale collaborative research into the condition.
Journal ArticleDOI

World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research

TL;DR: The Endometriosis Phenome and Biobanking Harmonization Project (EPhect) as discussed by the authors harmonizes standard operating procedures (SOPs) and standardizes the recording of associated data for collection, processing, and storage of fluid biospecimens relevant to endometria.
Journal ArticleDOI

Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer

TL;DR: Several traditional and new risk factors for ovarian cancer may be explained by their ability to induce M UC1 immunity through exposure of MUC1 to immune recognition in the context of inflammatory or hormonal processes in various MUC2-positive tissues.